S. Shen

发表

Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.

K. Lamborn, G. Denardo, S. Denardo, 1995, Cancer research.

Dosimetric and radiobiological impact of dose fractionation on respiratory motion induced IMRT delivery errors: a volumetric dose measurement study.

Jun Duan, Richard A Popple, Sui Shen, 2006, Medical physics.

A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy.

G. Denardo, S. Denardo, M. Groch, 1996, Nuclear medicine and biology.

Imaging glioma extent with 131I-TM-601.

A. Mamelak, J. Fiveash, S. Shen, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation.

Richard A Popple, Roger Ove, Sui Shen, 2002, International journal of radiation oncology, biology, physics.

Dosimetry for Targeted Radiotherapy

J. Fiveash, S. Shen, 2010 .

A novel phantom and procedure providing submillimeter accuracy in daily QA tests of accelerators used for stereotactic radiosurgery*

R. Popple, Xingen Wu, S. Shen, 2016, Journal of applied clinical medical physics.

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

S Shen, G L DeNardo, K. Lamborn, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

G. Denardo, S. Denardo, S. Shen, 1998, Anticancer research.

Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung.

G. Denardo, S. Denardo, S. Shen, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

S. Shen, R. Meredith, A. Lobuglio, 2005, Cancer biotherapy & radiopharmaceuticals.

Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.

G. Denardo, S. Denardo, S. Shen, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comprehensive evaluation of a commercial macro Monte Carlo electron dose calculation implementation using a standard verification data set.

R. Popple, J. Antolak, S. Shen, 2006, Medical physics.

Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.

G. Denardo, S. Denardo, J. Lehmann, 2006, International journal of radiation oncology, biology, physics.

Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.

G. Denardo, S. Denardo, S. Shen, 1997, Anticancer research.

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

J. Vose, M. Goris, S. Shen, 2004, Blood.

Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.

S. Shen, R. Meredith, E. Banaga, 2014, Cancer biotherapy & radiopharmaceuticals.

The use of endoscopic ultrasound-guided gold markers in image-guided radiation therapy of pancreatic cancers: a case series.

S. Varadarajulu, S. Shen, J. Trevino, 2010, Endoscopy.

Quantification of iodine-131 in tumors using a threshold based on image contrast

Shu Liao, K. Lamborn, G. Denardo, 1998, European Journal of Nuclear Medicine.

Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.

K. Lamborn, G. Denardo, S. Denardo, 1994, Cancer research.

Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3)

G. Denardo, S. Denardo, S. Shen, 1994, Cancer.

Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131 i‐lym‐1 as a model

G. Denardo, S. Denardo, S. Shen, 1994, Cancer.

SPLENIC VOLUME CHANGE AND THERAPUETIC RESPONSE IN PATIENTS TREATED WITH RADIOMMUNOCONJUGATES

G. Denardo, S. Denardo, S. Shen, 2005 .

Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.

K. Lamborn, G. Denardo, S. Denardo, 1996, Journal of Nuclear Medicine.

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

S. Shen, R. Meredith, S. Knox, 2013, Cancer biotherapy & radiopharmaceuticals.

Strategies for developing effective radioimmunotherapy for solid tumors.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.

E. Perez, K. Lamborn, G. Denardo, 1998, Anticancer research.

67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Copper-2-Iminothiolane-6-[ p-( Bromoacetamido ) benzyl ]-TETA-Lym-1 for Radioimmunotherapy of Non-Hodgkin ' s Lymphoma

S. Shen, D. Kukis, A. Yuan, 2007 .

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

J. Schlom, S. Shen, W. Grizzle, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

S. Shen, R. Meredith, E. Banaga, 2013 .

Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.

S. Shen, W. Grizzle, A. Forero, 2005, Cancer biotherapy & radiopharmaceuticals.

A novel monoclonal antibody design for radioimmunotherapy.

J. Schlom, S. Shen, A. Forero, 2003, Cancer biotherapy & radiopharmaceuticals.

67 Cu- versus 131 I-Labeled Lym-1 Antibody: Comparative Pharmacokinetics and Dosimetry in Patients with Non-Hodgkin’s Lymphoma 1

G. Denardo, S. Denardo, S. Shen, 1999 .

Reduced Margin Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancers

R. Popple, M. Dobelbower, S. Spencer, 2020, Cureus.

Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.

G. Denardo, S. Denardo, S. Shen, 1998, Cancer biotherapy & radiopharmaceuticals.

Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice

V. L. Alvarez, S. Shen, G. Gillespie, 2004, Journal of Neuro-Oncology.

Dosimetry for radioimmunotherapy: a rapidly evolving field.

G. Denardo, S. Shen, R. Wilder, 1999, Cancer biotherapy & radiopharmaceuticals.

Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.

S. Shen, R. Meredith, A. Lobuglio, 2003, Cancer biotherapy & radiopharmaceuticals.

Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer

G. Denardo, S. Denardo, S. Shen, 2001 .

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

R. Flavell, F. Feng, S. Shen, 2020, Clinical Cancer Research.

Lym-1 for Radioimmunotherapy of Non-Hodgkin's Lymphoma

S. Shen, D. Kukis, A. Yuan, 2007 .

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

G. Denardo, S. Denardo, S. Shen, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.

G. Denardo, S. Denardo, S. Shen, 1999, Nuclear medicine and biology.

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

K. Lamborn, G. Denardo, S. Denardo, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

acid (DOTA)-.Peptide-ChL6, a Novel linmunoconjugate with Catabolizable Linker, to 2-Iminothiolane-2- (p-(Bromoacetamido)benzyl)-DOTA-ChL6 in Breast Cancer Xenografts'

K. Lamborn, G. Denardo, S. Denardo, 1998 .

A Method to Correct for Radioactivity in Large Vessels That Overlap the Spine in Imaging-Based Marrow Dosimetry of Lumbar Vertebrae

S. Shen, A. Forero, R. Meredith, 2008, Journal of Nuclear Medicine.

Concentration in Blood and Body Practical Determination of Patient-Specific Marrow Dose Using Radioactivity

G. Denardo, S. Denardo, S. Shen, 2006 .

Clinically useful marrow dosimetry for targeted radionuclide therapy.

S. Shen, R. Meredith, 2005, Cancer biotherapy & radiopharmaceuticals.

Enhancement of 67Cu‐2IT‐BAT‐LYM‐1 therapy in mice with human burkitt's lymphoma (Raji) using interleukin‐2

K. Lamborn, G. Denardo, S. Denardo, 1997, Cancer.

ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas

A. Tolcher, C. Takimoto, A. Patnaik, 2004, Clinical Cancer Research.

Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.

G. Denardo, S. Denardo, S. Shen, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

First in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab

S. Shen, R. Alvarez, R. Meredith, 2013 .

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

M. Brechbiel, P. Roberson, S. Shen, 2005, Cancer biotherapy & radiopharmaceuticals.

A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Anticancer research.

Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator.

G. Denardo, S. Denardo, S. Shen, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

radioimmunotherapy for B-cell non-Hodgkin's lymphoma Phase I trial of a novel anti-CD20 fusion protein in pretargeted

J. Vose, S. Shen, A. Forero, 2013 .

Phase 1 trial of a novel anti-CD 20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

J. Vose, M. Goris, S. Shen, 2004 .

Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.

G. Denardo, S. Denardo, S. Shen, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma

S. Shen, A. Forero, G. Wiseman, 2010, Journal of Nuclear Medicine.

Dosimetrie Evaluation of Copper-64 in Copper-67-2IT-BAT-Lym-l for Radioimmunotherapy

S. Denardo, S. Shen, A. Yuan, 2006 .

Impact of splenomegaly on therapeutic response and I‐131‐LYM‐1 dosimetry in patients with B‐lymphocytic malignancies

G. Denardo, S. Denardo, S. Shen, 1997, Cancer.

Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.

S. Shen, J. Duan, I. Brezovich, 2003, Cancer biotherapy & radiopharmaceuticals.

Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.

G. Denardo, S. Denardo, S. Shen, 1999, Cancer biotherapy & radiopharmaceuticals.

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.

S. Shen, J. Duan, R. Meredith, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.

T. Jones, G. Denardo, S. Denardo, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A technique using 99mTc-mebrofenin SPECT for radiotherapy treatment planning for liver cancers or metastases.

S. Spencer, S. Shen, J. Duan, 2014, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Attenuation of intracavitary applicators in 192Ir-HDR brachytherapy.

R. Popple, S. Shen, J. Duan, 2004, Medical physics.

Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.

G. Denardo, S. Denardo, S. Shen, 2003, Cancer biotherapy & radiopharmaceuticals.

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

J. McGahan, K. Lamborn, G. Denardo, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer

J. Schlom, S. Shen, R. Meredith, 2004 .

Estimation of Radiation Absorbed Doses to the Red Marrow in Radioimmunotherapy

S. Shen, D. Macey, 1995, Clinical nuclear medicine.

Determination of field size‐dependent wedge factors from a few selected measurements

R. Popple, S. Shen, J. Duan, 2005, Journal of applied clinical medical physics.

166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.

J. Eary, R. Wendt, W. Erwin, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

J. McGahan, K. Lamborn, G. Denardo, 1998, Cancer biotherapy & radiopharmaceuticals.

Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.

G. Denardo, S. Denardo, S. Shen, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A dynamic supraclavicular field-matching technique for head-and-neck cancer patients treated with IMRT.

R. Popple, S. Spencer, S. Shen, 2004, International journal of radiation oncology, biology, physics.

MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan

Sui Shen, S. Shen, R. Meredith, 2009, Journal of Nuclear Medicine.

Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.

Sui Shen, Christine Hartmann-Siantar, Aina Yuan, 2005, Cancer biotherapy & radiopharmaceuticals.

Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.

R. Ceriani, G. Denardo, S. Denardo, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

K. Lamborn, G. Denardo, S. Denardo, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Stereotactic radiosurgery with MLC‐defined arcs: Verification of dosimetry, spatial accuracy, and end‐to‐end tests

B. Guthrie, M. Bredel, R. Popple, 2019, Journal of applied clinical medical physics.

Intraoperative Ultrasound Guidance During Intracavitary Brachytherapy Applicator Placement in Cervical Cancer: The University of Alabama at Birmingham Experience

Philip E. Schaner, Sharon A. Spencer, Sui Shen, 2013, International Journal of Gynecologic Cancer.

Effects of bladder distension on organs at risk in 3D image-based planning of intracavitary brachytherapy for cervical cancer.

Hui-Yi Lin, S. Spencer, S. Shen, 2010, International journal of radiation oncology, biology, physics.

High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

K. Lamborn, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Clinical lymphoma.

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

M. Gonda, B. Guthrie, A. Mamelak, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Practical simplifications for radioimmunotherapy dosimetric models

G. Denardo, S. Denardo, S. Shen, 1999 .

Practical determination of organ S values for individual patients for therapy.

G. Denardo, S. Denardo, S. Shen, 1997, Nuclear medicine and biology.

Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.

S. Shen, A. Forero, R. Meredith, 2011, Cancer biotherapy & radiopharmaceuticals.

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

S. Shen, A. Forero, R. Meredith, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Protein in Patients with Gastrointestinal Malignancies Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC 49 Fusion

Ruby, S. Shen, A. Forero, 2005 .

Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

Julien Torgue, Sui Shen, Jinda Fan, 2014, The Journal of Nuclear Medicine.

Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma

S. Shen, A. Forero, S. Awasthi, 2007, Leukemia & lymphoma.

Validation of target volume and position in respiratory gated CT planning and treatment.

Jun Duan, Richard A Popple, Sui Shen, 2003, Medical physics.

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.

G. Denardo, S. Shen, D. Kukis, 1999, Cancer biotherapy & radiopharmaceuticals.

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).

G. Denardo, S. Denardo, S. Shen, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

S. Bidlingmaier, Youngho Seo, Bin Liu, 2023, bioRxiv.

K. Lamborn, G. Denardo, S. Denardo, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reproducibility of operator processing for radiation dosimetry.

K. Lamborn, G. Denardo, S. Denardo, 1997, Nuclear medicine and biology.

Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter.

S Shen, G L DeNardo, G. Denardo, 1994, Medical physics.

Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trials.

S. Shen, T. Reid, B. Oronsky, 2022, American journal of cancer research.

End-to-end test of spatial accuracy in Gamma Knife treatments for trigeminal neuralgia.

R. Popple, Xingen Wu, S. Shen, 2014, Medical physics.

Image-based 3D treatment planning for vaginal cylinder brachytherapy: dosimetric effects of bladder filling on organs at risk.

S. Shen, J. F. De Los Santos, R. Kim, 2009, International journal of radiation oncology, biology, physics.

Factors Affecting ICRU Point Dose and 3-D Volume Dose for Organs at Risk in Image-based Intracavitary Brachytherapy Planning for Cervical Cancer

S. Spencer, S. Shen, R. Kim, 2008 .

Dose perturbation and inhomogeneity of multi-arrays of 125I seed-loaded stent for treatment of portal vein tumor thrombosis.

S. Shen, S. Ye, Seongmoon Jung, 2019, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

Imaging for improved prediction of myelotoxicity after radioimmunotherapy

G. Denardo, S. Denardo, S. Shen, 1997, Cancer.

Intensity modulation with respiratory gating for radiotherapy of the pleural space.

J. Fiveash, S. Shen, J. Duan, 2007, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

A phase I evaluation of intravenous (IV) 131I-chlorotoxin delivery to solid peripheral and intracranial tumors.

M. Wiranowska, N. Senzer, J. Raizer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosimetric effect of respiration-gated beam on IMRT delivery.

Jun Duan, Richard A Popple, Sui Shen, 2003, Medical physics.

SU-E-T-655: Quantifying the Dosimetric Characteristics of a Calypso Compatible Radiotherapy Treatment Couch with Angular Transmission Functions

Xizeng Wu, R. Popple, S. Shen, 2015 .

Conventional high-dose-rate brachytherapy with concomitant complementary IMRT boost: a novel approach for improving cervical tumor dose coverage.

Jun Duan, Sui Shen, Hui-Yi Lin, 2008, International journal of radiation oncology, biology, physics.

Performance of a Commercial Macro Monte Carlo Dose Calculation Algorithm for Determining Output Factors of Clinical Electron Fields

R. Popple, Xingen Wu, S. Shen, 2009, Technology in cancer research & treatment.

Model prediction of treatment planning for dose‐fractionated radioimmunotherapy

S. Shen, J. Duan, R. Meredith, 2002, Cancer.

Image-based three-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: dose-volume histograms of the bladder, rectum, sigmoid colon, and small bowel.

S. Shen, J. Duan, R. Kim, 2007, Brachytherapy.

Dose errors due to inhomogeneities in balloon catheter brachytherapy for breast cancer.

Siyong Kim, S. Shen, I. Brezovich, 2004, International journal of radiation oncology, biology, physics.

Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.

G. Denardo, S. Denardo, S. Shen, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.

S. Shen, A. Forero, J. Duan, 2005, Cancer biotherapy & radiopharmaceuticals.

Selection of brachytherapy applicators based on tumor size and shape for cervical cancer: simulation analysis of pear-shaped isodose dimensions.

S. Shen, S. Marcrom, R. Kim, 2021, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

A Practical Method to Prolong Expiratory Breath Holds for Abdominal Stereotactic Body Radiotherapy.

J. Fiveash, S. Shen, R. Jacob, 2021, International journal of radiation oncology, biology, physics.

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

R. Flavell, F. Feng, S. Shen, 2020, Clinical Cancer Research.

SU‐DD‐A1‐06: RapidArc Patient Specific Quality Assurance: Comparison with DMLC IMRT

Xizeng Wu, R. Popple, S. Shen, 2009 .

Assaying 192Ir line sources using a standard length well chamber.

Jun Duan, Richard A Popple, Sui Shen, 2002, Medical physics.